Victory Capital Management Inc. Has $394,000 Stock Holdings in Morphic Holding, Inc. (NASDAQ:MORF)

Victory Capital Management Inc. raised its holdings in Morphic Holding, Inc. (NASDAQ:MORF) by 10.8% in the fourth quarter, Holdings Channel.com reports. The fund owned 13,630 shares of the company’s stock after acquiring an additional 1,324 shares during the quarter. Victory Capital Management Inc.’s holdings in Morphic were worth $394,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Amalgamated Bank lifted its stake in Morphic by 14.0% in the third quarter. Amalgamated Bank now owns 4,859 shares of the company’s stock valued at $111,000 after acquiring an additional 597 shares during the last quarter. Quantbot Technologies LP acquired a new stake in Morphic in the third quarter valued at approximately $137,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Morphic by 38.1% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,182 shares of the company’s stock valued at $142,000 after acquiring an additional 1,705 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in Morphic by 364.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,753 shares of the company’s stock valued at $166,000 after acquiring an additional 4,515 shares during the last quarter. Finally, State Board of Administration of Florida Retirement System lifted its stake in Morphic by 14.0% in the third quarter. State Board of Administration of Florida Retirement System now owns 9,845 shares of the company’s stock valued at $226,000 after acquiring an additional 1,210 shares during the last quarter. 94.25% of the stock is currently owned by institutional investors and hedge funds.

Morphic Stock Up 11.0 %

NASDAQ:MORF opened at $30.80 on Friday. Morphic Holding, Inc. has a 12 month low of $19.34 and a 12 month high of $63.08. The firm has a market cap of $1.54 billion, a price-to-earnings ratio of -8.80 and a beta of 1.48. The company’s 50 day moving average is $30.28 and its 200-day moving average is $30.25.

Morphic (NASDAQ:MORF) last released its quarterly earnings results on Thursday, April 25th. The company reported ($0.91) EPS for the quarter, beating analysts’ consensus estimates of ($0.96) by $0.05. Research analysts predict that Morphic Holding, Inc. will post -4.07 EPS for the current fiscal year.

Morphic Company Profile

Morphic Holding, Inc, a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease.